• Dimerix receives ¥300 million (~AU$3.2 million) upfront payment from FUSO
• Dimerix anticipates further ¥400 million (~AU$4.1 million) on first development milestone
• Dimerix eligible for up to ¥3 billion (~AU$30.6 million) in development milestones and ¥6.8 billion (~AU$69.4 million) in sales milestones, plus 15-20% royalties

Dimerix Limited has received the initial upfront payment of ¥300 million (~AU$3.2 million) from FUSO Pharmaceutical Industries, Ltd. under the recently announced license agreement. Under the agreement, FUSO has been granted exclusive rights to commercialize DMX-200 for FSGS in Japan. Dimerix may become eligible to receive a further ¥400 million (~AU$4.1 million) on the first development milestone being achieved, which is anticipated to occur in the next 6-12 weeks. Additionally, Dimerix is eligible for further potential development milestone payments of up to ¥3.4 billion (~AU$30.6 million) and potential sales milestones of up to ¥6.8 billion (~AU$69.4 million), as well as being eligible for 15-20% royalties on net sales of DMX-200 if successfully commercialized. Dimerix now has three high-quality partners across multiple territories, providing strong support for the advancement and commercialization of DMX-200 as a potential new treatment for FSGS. Dimerix continues to focus on licensing opportunities with potential partners in territories not already covered, including the major markets of the US and China.

Dimerix may become eligible for up to ¥3 billion (~AU$30.6 million) in development milestones and ¥6.8 billion (~AU$69.4 million) in sales milestones, plus 15-20% royalties on net sales of DMX-200.

Dimerix continues to focus on licensing opportunities with potential partners in territories not already covered, including the major markets of the US and China.